AngioDynamics, Inc. Form 8-K Summary
Business Context and Reporting Period
AngioDynamics, Inc. (NASDAQ: ANGO), a Delaware corporation, filed this Current Report on Form 8-K on April 2, 2026. The filing announces financial results for the fiscal third quarter ended February 28, 2026. The company is headquartered in Latham, New York.
Key Financial Metrics
The provided text serves as a cover document referencing a press release (Exhibit 99.1) and presentation slides (Exhibit 99.2) containing the actual financial data. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this filing text. The filing text does not provide a clear value for these metrics.
Material Changes
No specific material changes versus the prior comparable period are detailed in the text of this Form 8-K. The document indicates that such details are contained within the attached press release and presentation materials.
Guidance, Outlook, and Risks
The filing includes a comprehensive "Forward-Looking Statements" section. Management notes that actual results may differ materially from expectations due to various risks, including:
- Global pandemic impacts (specifically referencing COVID-19).
- Product development challenges and competitor technological advances.
- Intellectual property infringement or defense.
- Regulatory actions by the FDA and other agencies.
- Economic conditions, including inflation, tariffs, labor shortages, and supply chain challenges.
- Pending or future litigation and clinical trial results.
- Foreign currency exchange rate fluctuations and pricing pressures from group purchasing organizations.
The company explicitly states it does not assume an obligation to publicly update or revise forward-looking statements.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2026 revenue, net income, and EPS figures.
- Examine Exhibit 99.2 (Presentation Slides) for updated full-year guidance and segment performance.
- Verify the status of any pending litigation or regulatory actions mentioned in the risk factors.
- Assess the impact of supply chain challenges and raw material costs on future margins as highlighted in the forward-looking statements.